Safety Profile and Clinical Recommendations for the Use of Lapatinib.
about
Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibitionManagement of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities
P2860
Safety Profile and Clinical Recommendations for the Use of Lapatinib.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Safety Profile and Clinical Recommendations for the Use of Lapatinib.
@ast
Safety Profile and Clinical Recommendations for the Use of Lapatinib.
@en
Safety Profile and Clinical Recommendations for the Use of Lapatinib.
@nl
type
label
Safety Profile and Clinical Recommendations for the Use of Lapatinib.
@ast
Safety Profile and Clinical Recommendations for the Use of Lapatinib.
@en
Safety Profile and Clinical Recommendations for the Use of Lapatinib.
@nl
prefLabel
Safety Profile and Clinical Recommendations for the Use of Lapatinib.
@ast
Safety Profile and Clinical Recommendations for the Use of Lapatinib.
@en
Safety Profile and Clinical Recommendations for the Use of Lapatinib.
@nl
P2860
P356
P1433
P1476
Safety Profile and Clinical Recommendations for the Use of Lapatinib.
@en
P2093
Dimitrios Chatsiproios
P2860
P356
10.1159/000285776
P577
2010-04-26T00:00:00Z